Sum of Pain Intensity Differences (SPID) in migraine trials. A comment based on four rizatriptan trials.
Sum of Pain Intensity Difference (SPID) is an outcome measure that summarizes treatment response over a clinically relevant period. SPID is widely reported in clinical trials of analgesics but has been little used in migraine trials. We compared SPID over 2 h with the standard migraine outcome measures of pain-free at 2 h and headache relief at 2 h using data from four published clinical trials of rizatriptan in migraine patients. In assessing treatment response (rizatriptan and sumatriptan versus placebo, rizatriptan versus sumatriptan, within-treatment dose effects), SPID usually yielded similar results to the more easily understood pain-free measure.
Tfelt-Hansen
P
P
Department of Neurology, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark. tfelt@inet.uni2.dk
McCarroll
K
K
Lines
C
C
D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology*; D017063:Outcome Assessment, Health Care; D010147:Pain Measurement; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*; D014363:Tryptamines
D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C093622:rizatriptan